Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
4502 · TSE · Japan · Health care
In shortTakeda Pharmaceutical Company Limited is loss-making, generates cash and carries moderate debt, with revenue stable (−1.7% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 0.1% | 17/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -3.4% | 6/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -2.1% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 0.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | – | n/a |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.66× | 75/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.89× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.02× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 19.2% | 97/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 2 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 4 | 58/100 |
| Revenue growth volatility | 6.0% | 89/100 |
| Operating margin volatility | 5.2% | 62/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 3.8% | 38/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
JPY millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,551 | 4,505,720 |
| Cost of revenue | – | – | – | 1,580,217 | 1,571,588 |
| Gross profit | – | – | – | 3,001,334 | 2,934,132 |
| Selling, general & admin | – | – | – | 1,104,766 | 1,084,215 |
| Operating income | – | – | – | 342,586 | 6,217 |
| Interest expense | – | – | – | 210,065 | 357,572 |
| Pre-tax income | 302,571 | 375,090 | 52,791 | 175,084 | (142,355) |
| Income tax | – | – | – | 66,941 | 9,770 |
| Net income | 230,059 | 317,017 | 144,067 | 107,928 | (152,390) |
| Diluted EPS | ¥145.87 | ¥201.94 | ¥91.16 | ¥67.23 | −¥96.75 |
Not computed: a required balance-sheet item is missing.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: EDINET (FSA Japan). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Mar 31, 2026 · Data updated Jun 17, 2026